Blumont Pharma Limited, Ocumont Eye Ointment 1% w/w defect
Class 4 medicines defect notification: The MHRA has published a Class 4 medicines defect notification for Ocumont Eye Ointment 1% w/w.
Published: 27 January 2026
The Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 4 medicines defect notification for Ocumont Eye Ointment 1% w/w.
Blumont Pharma Limited has informed the MHRA about the absence of Braille on the outer carton of one batch of Ocumont Eye Ointment 1% w/w (POM). It was identified that the Braille information was inadvertently omitted during the approval and release process.
Further information, advice and details of the affected batch can be found on the MHRA website.